natgillin/translations-raw huggingface dataset:
Det primære endepunkt var investigators vurdering af progressionsfri overlevelse (PFS) i henhold til RECIST 1.1; de vigtigste sekundære effektendepunkter omfattede objektiv responsrate (ORR), clinical benefit rate (CBR) og samlet overlevelse (OS). 
The primary endpoint was investigator-assessed progression-free survival (PFS) evaluated according to RECIST 1.1; key secondary efficacy endpoints included objective response rate (ORR), clinical benefit rate (CBR) and overall survival (OS).
• Uregelmæssige resultater af blodprøver vedrørende leverfunktionen 
• Abnormalities in liver blood tests
Verzenios indeholder natrium 
Verzenios contains sodium
Hos patienter med svær nyreinsufficiens bør abemaciclib administreres med forsigtighed og under tæt monitorering for tegn på toksicitet. 
Abemaciclib should be administered with caution in patients with severe renal impairment, with close monitoring for signs of toxicity.
c Venøse tromboemboliske hændelser omfatter DVT, lungeemboli, cerebral venøs sinustrombose, trombose i vena subclavia, vena axillaris, DVT i vena cava inferior og venetrombose i bækkenet. 
Venous thromboembolic events include DVT, pulmonary embolism, cerebral venous sinus thrombosis, subclavian, axillary vein thrombosis,DVT inferior vena cava and pelvic venous thrombosis
Meget almindelig Træthed 
Very common Fatigue
Anbefalinger vedrørende håndtering af hæmatologisk toksicitet 
Management recommendations for haematologic toxicities
Hos raske forsøgsdeltagere resulterede samtidig administration af abemaciclib og loperamid, som er et P-glycoprotein (P-gp)-substrat, i en stigning i plasmaeksponeringen for loperamid på 9 % baseret på AUC0-∞ og på 35 % baseret på Cmax. 
In healthy subjects, co-administration of abemaciclib and the P-glycoprotein (P-gp) substrate loperamide resulted in an increase in loperamide plasma exposure of 9% based on AUC0-∞ and 35% based on Cmax.
Niveauerne var forhøjede, men stabile, i hele behandlingsperioden, var reversible ved seponering af behandlingen og var ikke ledsaget af ændringer i markørerne for nyrefunktionen, såsom blodureanitrogen (BUN), cystatin C eller beregnet glomerulær filtrationshastighed (kalkuleret GFR) baseret på cystatin C. 
In clinical studies, increases in serum creatinine occurred within the first month of abemaciclib dosing, remained elevated but stable through the treatment period, were reversible upon treatment discontinuation, and were not accompanied by changes in markers of renal function, such as blood urea nitrogen (BUN), cystatin C, or calculated glomerular filtration rate based on cystatin C.
HR var 1,057 (95 % CI: 0,683; 1,633), p=0,8017. 
The HR was 1.057 (95% CI: 0.683, 1.633), p=0.8017.
Abemaciclibs indvirkning på andre lægemidlers farmakokinetik 
Effects of abemaciclib on the pharmacokinetics of other medicinal products
Investigators vurdering, antal hændelser (%) Median [måneder] (95 % CI) 
Investigator assessment, number of events Median [months] (95% CI)
Samtidig administration af abemaciclib og CYP3A4-hæmmere kan øge plasmakoncentrationen af abemaciclib. 
Co-administration of abemaciclib with CYP3A4 inhibitors can increase plasma concentrations of abemaciclib.
Abemaciclib metaboliseres primært via CYP3A4. 
Abemaciclib is primarily metabolised by CYP3A4.
Samtidig brug af CYP3A4-induktorer bør undgås på grund af risikoen for nedsat virkning af abemaciclib (se pkt. 
Concomitant use of CYP3A4 inducers should be avoided due to the risk of decreased efficacy of abemaciclib (see section 4.5).
Hos forsøgsdeltagere med svær leverinsufficiens (Child Pugh C) var AUC0-∞ for abemaciclib og potensjusteret ubundet abemaciclib plus dets aktive metabolitter forøget henholdsvis 2,1-foldigt og 2,4-foldigt. 
In subjects with severe hepatic impairment (Child Pugh C), the AUC0-∞ of abemaciclib and potency adjusted unbound abemaciclib plus its active metabolites increased 2.1-fold and 2.4-fold, respectively.
Afbryd doseringen, indtil toksiciteten bedres til baseline eller grad 1. 
Suspend dose until toxicity resolves to baseline or Grade 1.
Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 behandlede) 
Very common side effects (may affect more than 1 in 10 people)
Der blev rapporteret om neutropeni hos patienter, der fik abemaciclib. 
Neutropenia was reported in patients receiving abemaciclib.
Der bør iværksættes behandling med lægemidler mod diarré, såsom loperamid, ved det første tegn på løs afføring. 
Treatment with antidiarrhoeal agents, such as loperamide, should be started at the first sign of loose stools.
Der foreligger ingen data fra patienter med svær nyreinsufficiens, patienter med nyresygdom i slutstadiet eller dialysepatienter. 
There are no data in patients with severe renal impairment, end stage renal disease or in patients on dialysis.
Hos patienter med fremskreden og/eller metastatisk cancer resulterede samtidig administration af CYP3A4-hæmmeren clarithromycin i en 3,4-foldig stigning i plasmaeksponeringen for abemaciclib og i en 2,5-foldig stigning i den samlede ubundne potensjusterede plasmaeksponering for abemaciclib og dets aktive metabolitter. 
In patients with advanced and/or metastatic cancer, co-administration of the CYP3A4 inhibitor clarithromycin resulted in a 3.4-fold increase in the plasma exposure of abemaciclib and a 2.5-fold increase in the combined unbound potency adjusted plasma exposure of abemaciclib and its active metabolites.
I østrogenreceptor-positive brystcancercellelinjer forhindrede vedvarende targeteret hæmning med abemaciclib tilbagevenden af Rb-fosforylering, hvilket resulterede i cellesenescens og apoptose. 
In oestrogen receptor-positive breast cancer cell lines, sustained target inhibition with abemaciclib prevented rebound of Rb phosphorylation resulting in cell senescence and apoptosis.
Der foreligger ingen data vedrørende administration af abemaciclib hos patienter med svær nyreinsufficiens, patienter med nyresygdom i slutstadiet eller dialysepatienter (se pkt. 
There are no data regarding abemaciclib administration in patients with severe renal impairment, end stage renal disease, or in patients on dialysis (see section 5.2).
Bivirkningerne er angivet i nedenstående tabel efter systemorganklasse og hyppighed i henhold til MedDRA-konventionen. 
In the following tables, adverse reactions are listed in order of MedDRA body system organ class and frequency.
• Tabletkerne: kolloid silica, croscarmellosenatrium, lactosemonohydrat, mikrokrystallinsk cellulose, natriumstearylfumarat. 
• Tablet core: colloidal hydrated silica, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, sodium stearyl fumarate.
Verzenios er indiceret til behandling af kvinder med lokalt fremskreden eller metastatisk hormonreceptor (HR)-positiv, human epidermal vækstfaktorreceptor 2 (HER2)-negativ brystcancer i kombination med en aromatasehæmmer eller fulvestrant som indledende endokrinbaseret behandling, eller hos kvinder, der har fået forudgående endokrin behandling. 
Verzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.
Anbefalede dosisjusteringer i tilfælde af bivirkninger Verzenios-dosis kombinationsbehandling 
Dose adjustment recommendations for adverse reactions Verzenios dose combination therapy
Virkningen og sikkerheden af Verzenios i kombination med fulvestrant blev evalueret i MONARCH 2, et randomiseret, dobbeltblindet, placebokontrolleret fase 3-studie med kvinder med lokalt fremskreden eller metastatisk HR-positiv, HER2-negativ brystcancer. 
The efficacy and safety of Verzenios in combination with fulvestrant was evaluated in MONARCH 2, a randomised, double-blind, placebo-controlled phase 3 study in women with HR positive, HER2 negative locally advanced or metastatic breast cancer.
Hos patienter, som har fået deres dosis reduceret til 100 mg abemaciclib to gange dagligt, og hos hvem samtidig administration af en stærk CYP3A4-hæmmer ikke kan undgås, bør abemaciclibdosis reduceres yderligere til 50 mg to gange dagligt. 
In patients who have had their dose reduced to 100 mg abemaciclib twice daily and in whom co-administration of a strong CYP3A4 inhibitor cannot be avoided, the abemaciclib dose should be further reduced to 50 mg twice daily.
Thrombocytopeni Almindelig Lymfopeni Ikke almindelig Febril neutropeni 
Very common Neutropenia Leukopenia Anaemia Thrombocytopenia Common Lymphopenia Uncommon Febrile neutropenia
Aktivt stof: abemaciclib. 
- The active substance is abemaciclib.
MONARCH 3 - et randomiseret fase 3-studie: Verzenios i kombination med aromatasehæmmere 
Randomised Phase 3 Study MONARCH 3: Verzenios in combination with aromatase inhibitors
Samtidig administration af abemaciclib og den stærke CYP3A4-induktor rifampicin reducerede plasmakoncentrationen af abemaciclib med 95 % og den ubundne, potensjusterede plasmakoncentration af abemaciclib plus dets aktive metabolitter med 77 % baseret på AUC0-∞. 
Co-administration of abemaciclib with the strong CYP3A4 inducer rifampicin decreased the plasma concentration of abemaciclib by 95% and unbound potency adjusted plasma concentration of abemaciclib plus its active metabolites by 77% based on AUC0-∞.
Genotoksicitet 
Genotoxicity
Kvinder i den fertile alder skal anvende sikker kontraception (f.eks. dobbelt barrierekontraception) under behandlingen og i mindst 3 uger efter behandlingen (se pkt. 
Women of childbearing potential/Contraception in females Women of childbearing potential should use highly effective contraception methods (e.g. double-barrier contraception) during treatment and for at least 3 weeks after completing therapy (see section 4.5).
Grad 1 eller 2 
Grade 1 or 2
Hold ikke op med at tage Verzenios uden lægens anvisning. 
Do not stop taking Verzenios unless your doctor tells you to.
Du bør ikke amme, mens du tager Verzenios. 
You should not breast-feed while taking Verzenios.
Patienterne bør instrueres i, at de skal kontakte lægen i tilfælde af feber. 
Patients should be instructed to report any episode of fever to their healthcare provider.
Neutropeni blev indberettet hyppigt (45,1 %), og fald i neutrofiltallet af grad 3 eller 4 (baseret på laboratoriefund) blev indberettet hos 28,2 % af de patienter, der fik abemaciclib i kombination med aromatasehæmmere eller fulvestrant. 
and a Grade 3 or 4 decrease in neutrophil counts (based on laboratory findings) was reported in 28.2% of patients receiving abemaciclib in combination with aromatase inhibitors or fulvestrant.
Mediantiden til indtræden af neutropeni af grad 3 eller 4 var 29 til 33 dage, og mediantiden til bedring var 11 til 15 dage. 
The median time to onset of Grade 3 or 4 neutropenia was 29 to 33 days, and median time to resolution was 11 to 15 days.
Virkningen og sikkerheden af Verzenios i kombination med en aromatasehæmmer (anastrozol eller letrozol) blev vurderet i MONARCH 3, et randomiseret, dobbeltblindet, placebokontrolleret fase 3studie med kvinder med lokalt fremskreden eller metastatisk HR-positiv, HER2-negativ brystcancer, som ikke havde fået forudgående systemisk behandling i dette sygdomsregi. 
The efficacy and safety of Verzenios in combination with an aromatase inhibitor (anastrozole or letrozole) was evaluated in MONARCH 3, a randomised, double-blind, placebo-controlled phase 3 study in women with HR positive, HER2 negative locally advanced or metastatic breast cancer who had not received prior systemic therapy in this disease setting.
Objektiv responsrateb [%] (95 % CI) Komplet respons, (%) 
Objective response rateb [%] (95% CI) Complete response, (%) Partial response, (%)
Mediantiden til indtræden af ALAT-stigninger af grad 3 eller 4 var 57 til 61 dage, og mediantiden til bedring var 14 dage. 
The median time to onset of Grade 3 or 4 ALT elevation was 57 to 61 days, and median time to resolution was 14 days.
Indlægsseddel: Information til patienten Verzenios 50 mg filmovertrukne tabletter Verzenios 100 mg filmovertrukne tabletter Verzenios 150 mg filmovertrukne tabletter abemaciclib Dette lægemiddel er underlagt supplerende overvågning. 
Package leaflet: Information for the patient Verzenios 50 mg film-coated tablets Verzenios 100 mg film-coated tablets Verzenios 150 mg film-coated tablets abemaciclib This medicine is subject to additional monitoring.
CYP3A4-induktorer 
CYP3A4 inducers
Det anbefales at justere dosis hos patienter, der får diarré ≥ grad 2 (se pkt. 
Dose modification is recommended for patients who develop ≥ Grade 2 diarrhoea (see section 4.2).
Træthed og diarré kan forekomme i tilfælde af overdosering af abemaciclib. 
In the event of an abemaciclib overdose, fatigue and diarrhoea may occur.
Første dosisjustering 
First dose adjustment
- forårsage et fald i antallet af hvide blodlegemer og øge din risiko for at få en infektion. 
Verzenios may: - reduce the number of your white blood cells, and you may be at greater risk of getting an infection.
Der blev rapporteret om stigninger i ALAT og ASAT hos patienter, der fik abemaciclib. 
Increases in ALT and AST were reported in patients receiving abemaciclib.
100 mg to gange dagligt 
100 mg twice daily
herunder alder (<65 eller ≥65 år), race, geografisk region, sygdomssted, resistens over for endokrin behandling, tilstedeværelse af målbar sygdom, progesteronreceptorstatus og menopausal status. 
A series of prespecified subgroup PFS analyses showed consistent results across patient subgroups including age (<65 or ≥65 years), race, geographic region, disease site, endocrine therapy resistance, presence of measurable disease, progesterone receptor status, and menopausal status.
De primære effektresultater er opsummeret i tabel 8 og figur 2. 
The study met its primary endpoint of improving PFS. Primary efficacy results are summarised in Table 8 and Figure 2.
Øvrige indholdsstoffer: 
- The other ingredients in this medicine are:
Grad 3 
Grade 3
Median-PFS blev signifikant forlænget i den arm, der fik Verzenios plus fulvestrant (HR på 0,553 [95% CI 0,449; 0,681]); median-PFS var 16,4 måneder versus 9,3 måneder i den arm, der fik placebo plus fulvestrant. 
Median PFS was significantly prolonged in the Verzenios plus fulvestrant arm (HR of 0.553 [95% CI 0.449, 0.681]); median PFS was 16.4 months versus 9.3 months in the placebo plus fulvestrant arm.
Hvid, oval tablet på 6,6 x 12,0 mm, der er præget med “Lilly” på den ene side og“100” på den anden side. 
White, oval tablet of 6.6 x 12.0 mm, debossed with “Lilly” on one side and “100” on the other.
Brug af anden medicin sammen med Verzenios 
Other medicines and Verzenios
Samtidig brug af stærke CYP3A4-hæmmere bør undgås. 
Concomitant use of strong CYP3A4 inhibitors should be avoided.
De primære effektresultater er opsummeret i tabel 7 og figur 1. 
The study met its primary endpoint of improving PFS. Primary efficacy results are summarised in Table 7 and Figure 1.
Den progressionsfri overlevelse (PFS) blev signifikant forlænget i den arm, der fik Verzenios plus aromatasehæmmer (AI), (hazard ratio [HR] på 0,540 [95 % CI, 0,418 til 0,698]); median-PFS var 28,18 måneder i den arm, der fik Verzenios plus AI, og 14,76 måneder i den arm, der fik placebo plus AI. 
Progression-free survival (PFS) was significantly prolonged in the Verzenios plus aromatase inhibitor (AI) arm, (Hazard Ratio [HR] of 0.540 [95% CI, 0.418 to 0.698]); median PFS was 28.18 months in the Verzenios plus AI arm and was 14.76 months in the placebo plus AI arm.
Der blev set en reduktion i risikoen for sygdomsprogression eller død hos patienter med visceral sygdom (HR på 0,481 [95 % CI: 0,369; 0,627], median-PFS 14,7 måneder versus 6,5 måneder); hos patienter med sygdom i knoglerne alene (HR på 0,543 [95 % CI: 0,355; 0,833]); patienter med målbar sygdom (HR på 0,523, [95 % CI: 0,412; 0,644]). 
A reduction in the risk of disease progression or death was observed in patients with visceral disease, (HR of 0.481 [95% CI: 0.369, 0.627]), median PFS 14.7 months versus 6.5 months; in patients with bone-only disease (HR of 0.543 [95% CI: 0.355, 0.833]); patients with measurable disease (HR of 0.523 [95% CI: 0.412, 0.644]).
Grad 1 
Grade 1
≥1.500/mm3, trombocytter ≥100.000/mm3 og hæmoglobin ≥8 g/dl. 
Before treatment initiation, absolute neutrophil counts (ANC) ≥1500/mm3, platelets ≥100,000/mm3, and haemoglobin ≥8 g/dL are recommended.
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 behandlede) 
Common side effects (may affect up to 1 in 10 people)
Anden dosisjustering 
Second dose adjustment
Der blev set en reduktion i risikoen for sygdomsprogression eller død hos patienter med visceral sygdom (HR på 0,567 [95 % CI: 0,407; 0,789]), median-PFS 21,6 måneder versus 14,0 måneder; hos patienter med sygdom i knoglerne alene (HR 0,565, [95 % CI: 0,306; 1,044]); og hos patienter med målbar sygdom (HR 0,517, [95 % CI: 0,392; 0,681]). 
A reduction in the risk of disease progression or death was observed in patients with visceral disease, (HR of 0.567 [95% CI: 0.407, 0.789]), median PFS 21.6 months versus 14.0 months; in patients with bone-only disease (HR 0.565, [95% CI: 0.306, 1.044]); and in patients with measurable disease (HR 0.517, [95% CI: 0.392, 0.681]).
Gul, oval tablet på 7,5 x 13,7 mm, der er præget med “Lilly” på den ene side og“150” på den anden side. 
Yellow, oval tablet of 7.5 x 13.7 mm, debossed with “Lilly” on one side and “150” on the other.
Mediantiden til indtræden af ASAT-stigninger af grad 3 eller 4 var 71 til 185 dage, og mediantiden til bedring var 13 til 15 dage. 
The median time to onset of Grade 3 or 4 AST elevation was 71 to 185 days, and median time to resolution was 13 to 15 days.
Infektioner/parasitære sygdomme 
Infections/infestations
Nedsat nyrefunktion Det er ikke nødvendigt at justere dosis hos patienter med let eller moderat nyreinsufficiens. 
No dose adjustments are necessary in patients with mild or moderate renal impairment.
Beige, oval tablet på 5,2 x 9,5 mm, der er præget med “Lilly” på den ene side og“50” på den anden side. 
Beige, oval tablet of 5.2 x 9.5 mm, debossed with “Lilly” on one side and “50” on the other.
• Filmovertræk: titandioxid (E171), talcum (E553b), polyvinylalkohol (E1203), macrogol 3350 (E1521), gul jernoxid (E172) [kun 50 mg og 150 mg tabletter], rød jernoxid (E172) [kun 50 mg tabletter]. 
• Film-coating: titanium dioxide (E171), talc (E553b), polyvinyl alcohol (E1203), macrogol 3350 (E1521), iron oxide yellow (E172) [50 mg and 150 mg tablets only], iron oxide red (E172) [50 mg tablets only].
50 mg to gange dagligt 
50 mg twice daily
150 mg to gange dagligt 
150 mg twice daily
Det anbefales at justere dosis hos patienter, der udvikler neutropeni af grad 3 eller 4 (se pkt. 
Dose modification is recommended for patients who develop Grade 3 or 4 neutropenia (see section 4.2).
Responsvarighed [måneder] (95 % CI) 
Duration of response [months] (95%CI)
Det anbefales at justere dosis hos patienter, der udvikler ALAT- eller ASAT-stigninger af grad 3 eller 4 (se pkt. 
Dose modification is recommended for patients who develop Grade 3 or 4 ALT or AST increase (see section 4.2).
Samtidig brug af stærke CYP3A4-hæmmere og abemaciclib bør undgås. 
Use of strong CYP3A4 inhibitors together with abemaciclib should be avoided.
Verzenios plus aromatasehæmmer 
Verzenios plus aromatase inhibitor
• Hårtab 
• Hair loss
Objektiv responsrateb [%] (95 % CI) 
Objective response rateb [%] (95% CI)
MONARCH 3: Oversigt over effektdata (investigators vurdering, intent-to-treatpopulation) 
MONARCH 3: Summary of efficacy data (Investigator assessment, intent-to-treat population)
Du finder yderligere oplysninger om ovennævnte bivirkninger i afsnit 2. 
Refer to Section 2 for more information on any of the possible effects listed above.
Grad 2 
Grade 2
MONARCH 2: Kaplan-Meier-kurve over progressionsfri overlevelse (investigators vurdering, intent-to-treat-population) 
MONARCH 2: Kaplan-Meier plot of progression-free survival (Investigator assessment, intent-to-treat population)
Abemaciclib og dets aktive hovedmetabolitter hæmmer de renale transportører organisk kationtransportør 2 (OCT2), multidrug and extrusion toxin protein (MATE1) og MATE2-K. In vivointeraktioner mellem abemaciclib og klinisk relevante substrater for disse transportører, såsom dofetilid eller kreatinin, kan forekomme (se pkt. 
Medicinal products that are substrates of transporters Abemaciclib and its major active metabolites inhibit the renal transporters organic cation transporter 2 (OCT2), multidrug and extrusion toxin protein (MATE1), and MATE2-K.
• lægemidler, der kan øge indholdet af Verzenios i blodet: o Clarithromycin (et antibiotikum, der anvendes til behandling af bakterieinfektioner) 
o Clarithromycin (antibiotic used to treat bacterial infections)
Verzenios indeholder lactose 
Verzenios contains lactose
MONARCH 3: Kaplan-Meier-kurve over progressionsfri overlevelse (investigators vurdering, intent-to-treat-population) 
MONARCH 3: Kaplan-Meier plot of progression-free survival (Investigator assessment, intent-to-treat population)
MONARCH 2: Oversigt over effektdata (investigators vurdering, intent-to-treatpopulation) 
MONARCH 2: Summary of efficacy data (Investigator assessment, intent-to-treat population)
Det er særligt vigtigt, at du fortæller det til lægen eller apotekspersonalet, hvis du tager nedenstående: 
In particular, tell you doctor or pharmacist before taking Verzenios if you are taking the following:
Der blev rapporteret om lungeinfektion uden samtidig neutropeni hos patienter, der fik abemaciclib. 
Lung infection was reported in patients receiving abemaciclib without concurrent neutropenia.
Verzenios 50 mg filmovertrukne tabletter Verzenios 100 mg filmovertrukne tabletter Verzenios 150 mg filmovertrukne tabletter 
Verzenios 50 mg film-coated tablets Verzenios 100 mg film-coated tablets Verzenios 150 mg film-coated tablets
Vedvarende eller tilbagevendende grad 2 efter genoptagelse af den samme dosis til trods for maksimale understøttende tiltag Afbryd doseringen, indtil toksiciteten bedres til grad 1 eller derunder. 
Grade 2 that persists or recurs after resuming the same dose despite maximal supportive measures
Samtidig brug af CYP3A4-induktorer 
Concomitant use of inducers of CYP3A4
Hvis du har taget for meget Verzenios 
If you miss a dose of Verzenios
Afbryd doseringen, indtil toksiciteten bedres til grad 2 eller derunder. 
Suspend dose until toxicity resolves to Grade 2 or less.
Abemaciclib metaboliseres i leveren. 
Abemaciclib is metabolised in the liver.
- Verzenios 150 mg filmovertrukne tabletter er gule, ovale tabletter, der er præget med “Lilly” på den ene side og “150” på den anden side. 
- Verzenios 150 mg film-coated tablets are yellow, oval tablets debossed with “Lilly” on one side and “150” on the other.
Det er ikke nødvendigt at justere dosis. 
No dose adjustment required.
Påbegynd behandling med midler mod diarré, såsom loperamid, ved det første tegn på diarré. 
At the first sign of diarrhoea, start treatment with antidiarrhoeal agents, such as loperamide.
Uafhængig radiografisk gennemgang, antal hændelser (%) 
Independent radiographic review, number of events (%) Median [months] (95% CI)
Hos præ-/perimenopausale patienter var hazard ratio 0,415 (95 % CI: 0,246; 0,698); hos patienter, der var progesteronreceptornegative, var HR 0,509 (95 % CI: 
0.246, 0.698); in patients who were progesterone receptor negative, the HR was 0.509 (95% CI: 0.325,
Verzenios 100 mg filmovertruktne tabletter polyvinylalkohol (E1203) titandioxid (E171) macrogol (E1521) talcum (E553b) 
Verzenios 100 mg film-coated tablets polyvinyl alcohol (E1203) titanium dioxide (E171) macrogol (E1521) talc (E553b)
- Verzenios 50 mg filmovertrukne tabletter er beige, ovale tabletter, der er præget med “Lilly” på den ene side og “50” på den anden side. 
- Verzenios 50 mg film-coated tablets are beige, oval tablets debossed with “Lilly” on one side and “50” on the other.
Søn. 
Sun.
Se den anbefalede dosering af den endokrine behandling i produktresuméet for det pågældende lægemiddel. 
Please refer to the Summary of Product Characteristics of the endocrine therapy combination partner for the recommended posology.
Filmovertræk 
Posology